within Pharmacolibrary.Drugs.ATC.M;

model M02AA13
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.3833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0175,
    Tlag           = 600,            
    Vdp             = 0.009,
    k12             = 0.685,
    k21             = 0.685
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M02AA13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) widely used for its analgesic, antipyretic, and anti-inflammatory effects. It is commonly used for the treatment of mild to moderate pain, inflammation, and fever. Ibuprofen is an over-the-counter medication and is approved for clinical use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Robson, R (2015). Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. <i>Clinical drug investigation</i> 35(10) 625–632. DOI:<a href=\"https://doi.org/10.1007/s40261-015-0320-8\">10.1007/s40261-015-0320-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26334726/\">https://pubmed.ncbi.nlm.nih.gov/26334726</a></p></li><li><p>Edison, PE, et al., &amp; Chowbay, B (2022). Pharmacokinetics of oral versus intravenous ibuprofen for closure of patent ductus arteriosus: A pilot randomised controlled study. <i>Journal of paediatrics and child health</i> 58(3) 397–403. DOI:<a href=\"https://doi.org/10.1111/jpc.15720\">10.1111/jpc.15720</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34477275/\">https://pubmed.ncbi.nlm.nih.gov/34477275</a></p></li><li><p>Gelbenegger, G, &amp; Jilma, B (2022). Clinical pharmacology of antiplatelet drugs. <i>Expert review of clinical pharmacology</i> 15(10) 1177–1197. DOI:<a href=\"https://doi.org/10.1080/17512433.2022.2121702\">10.1080/17512433.2022.2121702</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36065676/\">https://pubmed.ncbi.nlm.nih.gov/36065676</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M02AA13;
